Zepbound (Tirzepatide) for Obesity

Overview
Zepbound is approved by the U.S. Food and Drug Administration (FDA) to help reduce and manage excess body weight in adults with obesity or overweight who have at least one weight-related comorbid condition, such as type 2 diabetes or high blood pressure. This medication is prescribed in conjunction with a reduced-calorie diet and increased physical activity. Zepbound is also FDA-approved for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is also known by its drug name, tirzepatide.

Zepbound belongs to a class of drugs known as dual GIP and glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the actions of two naturally occurring hormones involved in appetite and blood sugar regulation. Scientists believe that by targeting both GIP and GLP-1 receptors, Zepbound promotes feelings of fullness, reduces food intake, and enhances insulin sensitivity, which together lead to significant weight loss over time.

How do I take it?
Prescribing information states that Zepbound is administered as a subcutaneous (under the skin) injection once weekly. The starting dose is typically taken for four weeks, after which the dose is gradually increased every four weeks until the recommended maintenance dose is achieved. Weekly maintenance doses range in size, depending on individual response and tolerability. Zepbound should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia (indigestion), injection site reactions, fatigue, hypersensitivity reactions (allergic reactions), eructation (belching), hair loss, and gastroesophageal reflux disease (GERD).

Rare but serious side effects may include thyroid C-cell tumors, pancreatitis (inflammation of the pancreas), acute kidney injury, gallbladder disease, severe gastrointestinal issues, hypoglycemia (low blood sugar) when used with certain other medications, diabetic retinopathy (damage to the retina) complications in people type 2 diabetes, and suicidal thoughts or behaviors. 

For more information about this treatment, visit:

Zepbound (Tirzepatide) Injection, for Subcutaneous Use — Eli Lilly

Label: Zepbound — Tirzepatide Injection, Solution — DailyMed